Content continues after advertisement

Canine Paraneoplastic Hypertrophic Osteopathy

Clinician's Brief (Capsule)

Oncology

|March 2016

Sign in to Print/View PDF

This capsule is part of the WSAVA Global Edition of Clinician’s Brief.

Paraneoplastic hypertrophic osteopathy (pHO), usually associated with primary or metastatic pulmonary neoplasia in dogs, is a syndrome of painful swelling and periosteal bone proliferation of the distal limbs. It has been documented in humans and dogs, but the pathogenesis is unknown. 

This study retrospectively evaluated presenting concerns, physical findings, and clinical pathologic and radiographic findings in the medical records of 30 dogs diagnosed with pHO. A wide range of breeds and ages were represented. The authors found that the most common presenting concerns included symmetrical swelling of the entire or distal limbs (26/30). All limbs were affected in most cases (15/26). Additional clinical signs were lameness (23/30), ocular discharge or episcleral injection (23/30), lethargy (22/30), decreased appetite (15/30), fever (11/30), pain on palpation of extremities (11/30), coughing (9/30), heat on palpation of limbs (6/30), and inability to rise or walk (3/30). Clinical pathologic findings included anemia (13/20), neutrophilia (11/20), and elevated serum alkaline phosphatase (11/18). 

Neoplastic pulmonary nodules were present in all dogs. The most common primary malignancy was osteosarcoma, which may reflect both the high prevalence of this cancer in dogs and its tendency to metastasize to the lungs. Other tumor types included transitional cell carcinoma, leiomyosarcoma, fibrosarcoma, prostatic carcinoma, and renal carcinoma. Primary pulmonary adenocarcinoma was found in 3 dogs. The relationship between pHO and ocular signs seen in the majority of dogs was unclear. Prospective studies are warranted to better understand the cause of these clinical findings in dogs with pHO. 

Global Commentary

Presence of pHO is typically indicative of advanced disease status and is a negative prognostic indicator in most cases. Treatment is challenging and involves either addressing the primary neoplasia or secondarily addressing associated signs. The outcome is often best in patients that have solitary disease (eg, primary lung tumor) in which complete resection is possible and could potentially lead to pHO resolution. However, the vast majority of pHO is caused by metastatic pulmonary disease and effective, durable therapies are few and far between. Besides surgical resection of solitary gross disease, treatment options include systemic chemotherapy, NSAIDs or corticosteroids, multimodal pain control (eg, tramadol, gabapentin, acupuncture), bisphosphonates, and vagotomy.—Kelvin Kow, DVM, MS, DACVIM 

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy